Last updated: September 15, 2026
Pegloticase, marketed as Krystexxa, is a high-value biologic for adults with chronic gout refractory to conventional therapy. Its commercial growth has been driven by expanded diagnosis, specialist adoption, improved infusion management, and the 2022 FDA approval of co-administration with methotrexate. The product generated several hundred million dollars in annual sales before Horizon Therapeutics was acquired by Amgen in 2023. It remains commercially protected by manufacturing complexity, limited approved competition, physician familiarity, and the absence of an approved biosimilar.
The principal market risk is not immediate generic substitution. It is long-term price pressure from biosimilars, payer restrictions, treatment-center economics, and the development of oral urate-lowering or uricase-based alternatives.
What is pegloticase and how does Krystexxa work?
Pegloticase is a PEGylated recombinant uricase enzyme administered by intravenous infusion. It converts uric acid into allantoin, which is more soluble and readily eliminated. The mechanism differs from xanthine oxidase inhibitors such as allopurinol and febuxostat, which reduce uric acid production rather than directly degrading circulating urate.
The FDA approved Krystexxa in 2010 for chronic gout in adults who have failed or cannot tolerate conventional therapy and remain hyperuricemic. The labeled dose is 8 mg administered intravenously every two weeks. Patients are screened for glucose-6-phosphate dehydrogenase deficiency because hemolysis and methemoglobinemia are important safety risks in deficient patients. Infusion reactions and anti-drug antibodies also affect treatment persistence. [1]
In 2022, the FDA approved Krystexxa with oral methotrexate to improve response rates and reduce immunogenicity. The approval was based on the MIRROR randomized trial, in which methotrexate co-therapy improved sustained urate response and reduced infusion reactions and treatment discontinuations compared with pegloticase alone. [2]
What patient population does pegloticase target?
The addressable population is narrower than the overall gout market. Krystexxa targets patients with:
- Chronic refractory gout
- Persistent hyperuricemia despite oral urate-lowering therapy
- Tophi or substantial disease burden
- Inadequate response, intolerance, or contraindication to allopurinol and febuxostat
- Sufficient clinical need to justify intravenous biologic treatment
This positioning supports premium pricing but limits volume. Pegloticase is generally used after failure of lower-cost oral therapies, not as first-line gout treatment.
How large is the pegloticase market?
The U.S. is the core commercial market for Krystexxa. The product’s economics depend more on treatment intensity and persistence than on broad prevalence of gout. Chronic refractory gout is uncommon relative to total gout, but patients who receive pegloticase can generate substantial annual revenue because treatment is administered every two weeks and typically requires infusion-center services.
Market expansion has come from several sources:
- Greater identification of patients with uncontrolled gout.
- Increased rheumatologist awareness of biologic urate depletion.
- Use of methotrexate to improve treatment durability.
- Earlier referral of patients with tophaceous disease.
- Commercial infrastructure established by Horizon and continued by Amgen.
- Reimbursement support for a high-cost infused therapy.
The principal commercial constraint is treatment eligibility. Physicians must manage infusion logistics, premedication, laboratory monitoring, antibody development, and discontinuation when serum uric acid rises above the treatment threshold.
What is the financial trajectory of Krystexxa?
Krystexxa became one of Horizon Therapeutics’ key growth assets before Amgen acquired the company. Horizon expanded the product through specialist sales, reimbursement support, and the methotrexate co-therapy strategy.
Public company disclosures show a sharp increase in Krystexxa revenue during Horizon’s ownership, followed by integration into Amgen’s larger commercial portfolio.
| Period |
Commercial owner |
Financial significance |
| 2010 |
Savient Pharmaceuticals |
FDA approval of Krystexxa |
| 2015 |
Horizon Therapeutics |
Horizon acquired Krystexxa rights and related assets from Savient |
| 2020-2022 |
Horizon Therapeutics |
Revenue grew as specialist penetration and treatment adoption increased |
| 2022 |
Horizon Therapeutics |
Methotrexate co-therapy received FDA approval |
| October 2023 |
Amgen |
Amgen completed its acquisition of Horizon |
| 2023 onward |
Amgen |
Krystexxa became part of Amgen’s inflammation and rare-disease portfolio |
Horizon reported Krystexxa net sales of approximately $738 million in 2022, according to its annual reporting. The company identified Krystexxa as a major growth product alongside Tepezza and Uplizna. [3]
Amgen’s reporting structure after the acquisition does not always provide the same historical product-level detail previously supplied by Horizon. The acquisition therefore reduces visibility into standalone annual Krystexxa performance, although Amgen continues to identify the product as a commercial asset in its inflammation portfolio. [4]
What drives Krystexxa revenue?
Krystexxa revenue is primarily determined by four variables:
| Revenue driver |
Commercial effect |
| Number of treated patients |
Expands the patient base and infusion volume |
| Treatment persistence |
Extends revenue per patient |
| Methotrexate co-therapy |
Can improve response durability and reduce discontinuation |
| Net price and payer mix |
Determines revenue after discounts, rebates, and patient assistance |
The methotrexate label expansion has strategic importance because immunogenicity and loss of response were material barriers to long-term treatment. A higher sustained-response rate can increase lifetime revenue per patient, although concomitant methotrexate introduces monitoring, contraindications, and adherence requirements.
When does pegloticase lose exclusivity?
Pegloticase does not follow the conventional small-molecule exclusivity model. It is a biologic licensed under a biologics license application, or BLA, and biosimilar competition is governed primarily by the Public Health Service Act and FDA Purple Book framework.
The product received FDA approval in August 2010. Reference-product biologic exclusivity generally lasts 12 years from the date of first licensure under U.S. law. That period therefore expired in or around August 2022, subject to statutory calculations and the precise date of first licensure. [5]
The end of regulatory exclusivity did not create automatic competition. A biosimilar sponsor still needs to complete development, file an application under the 351(k) pathway, obtain FDA approval, and address any applicable patent issues.
What is the Orange Book status of pegloticase?
Krystexxa is not a conventional small-molecule drug and is not analyzed through the Orange Book in the same way as tablets, capsules, or injectable small molecules. Biologic reference products are tracked through the FDA Purple Book. The Orange Book does not provide the primary exclusivity framework for pegloticase. [5,6]
The relevant competitive question is whether a biosimilar or interchangeable biosimilar can be approved and commercially launched, not whether an ANDA applicant can enter through the standard generic pathway.
How strong is the pegloticase patent estate?
Pegloticase’s commercial protection rests on a combination of regulatory exclusivity, formulation and manufacturing know-how, clinical data, and potential patent rights involving the recombinant enzyme, PEG conjugation, production processes, dosing, and combination treatment.
The principal legal distinction is that biologic competition can remain difficult after core composition patents expire. Manufacturing a consistent PEGylated recombinant enzyme requires control of:
- Recombinant uricase expression
- Protein purification
- PEG conjugation
- Conjugate distribution and characterization
- Aggregate control
- Potency and impurity testing
- Stability through shipping and infusion use
These manufacturing barriers raise development costs and can delay biosimilar entry even without a broad blocking patent.
The methotrexate regimen also created a newer layer of commercial differentiation. Patents and regulatory exclusivity relating to co-therapy, dosing, patient selection, or treatment response may affect the commercial scope of competing products, although the practical value of method-of-use rights depends on claim breadth and enforcement.
A precise current patent-by-patent freedom-to-operate analysis requires review of live U.S. and foreign family members, terminal disclaimers, patent-term adjustments, maintenance fees, and claim construction. The public regulatory record establishes the product’s biologic status and approval history, but it does not by itself establish that every potentially relevant patent remains enforceable.
Are there Paragraph IV challenges to Krystexxa?
Paragraph IV litigation is an ANDA mechanism for small-molecule drugs. It is not the standard route for challenging a biologic such as pegloticase.
For Krystexxa, the relevant competitive pathway is a biosimilar application under section 351(k). Biosimilar sponsors may still challenge or litigate patents, but those disputes arise through the biologics patent-disclosure and notice framework rather than a traditional Orange Book Paragraph IV certification.
No approved pegloticase biosimilar was identified in the FDA Purple Book through the latest publicly available regulatory records reviewed for this analysis. [6]
What biosimilar risk exists for pegloticase?
Biosimilar risk is real but likely to develop gradually. Pegloticase has several characteristics that make biosimilar development more demanding than development of a simpler protein:
- It is a PEGylated enzyme rather than an unmodified monoclonal antibody.
- The active product is a heterogeneous conjugate population.
- Immunogenicity directly affects efficacy and safety.
- The product requires intravenous administration and infusion monitoring.
- The target population is specialized and relatively small.
- A biosimilar sponsor would need an effective rheumatology and infusion-center commercial network.
The commercial incentive remains meaningful because Krystexxa has generated hundreds of millions of dollars in annual sales. The market may support one or more biosimilar entrants if a sponsor can establish adequate interchangeability, secure payer access, and compete on net price.
The most likely initial biosimilar strategy is a price discount rather than an immediate 50% or greater reduction. Infused biologics often retain substantial physician and payer inertia after biosimilar approval, particularly when treatment response and immunogenicity are clinically important.
What competitive products threaten pegloticase?
Pegloticase competes with oral urate-lowering therapy more than with another approved intravenous uricase product.
| Competitor or class |
Relationship to pegloticase |
Competitive effect |
| Allopurinol |
First-line xanthine oxidase inhibitor |
Limits use of high-cost biologic therapy |
| Febuxostat |
Alternative xanthine oxidase inhibitor |
Retains patients before biologic escalation |
| Probenecid |
Uricosuric therapy |
Relevant in selected patients with residual renal function |
| Lesinurad |
Previously approved uricosuric used with xanthine oxidase inhibitors |
Historical competitor; U.S. commercial availability ended |
| Investigational uricases |
Potential direct competitors |
Could challenge infusion burden, immunogenicity, or dosing frequency |
| Pegloticase biosimilars |
Direct future competition |
Could reduce net price and payer leverage |
The most serious future threat would be a uricase product with lower immunogenicity, less frequent dosing, subcutaneous administration, or a more convenient infusion profile. Such a product could compete on clinical convenience even without a major price discount.
What licensing deals and ownership changes affect pegloticase?
The major ownership transaction was Horizon Therapeutics’ acquisition of Krystexxa from Savient Pharmaceuticals in 2015. Horizon paid approximately $145 million for the product and related rights, according to contemporaneous company disclosures. [7]
Amgen later acquired Horizon in a transaction valued at approximately $27.8 billion, with the transaction closing in October 2023. Krystexxa became part of Amgen’s portfolio together with Tepezza, Uplizna, and other specialty products. [4]
The acquisition changed Krystexxa’s commercial context:
- Horizon had a concentrated specialty-pharma model and relied heavily on product-level growth.
- Amgen has broader manufacturing, market-access, regulatory, and international capabilities.
- Krystexxa gained access to a larger infrastructure but became less prominent in public product-level reporting.
- Amgen can integrate Krystexxa with its inflammation and rare-disease commercial operations.
- The product’s revenue contribution is smaller relative to Amgen’s total sales than it was relative to Horizon’s revenue base.
What is the FDA regulatory status of pegloticase?
Krystexxa remains FDA-approved for chronic refractory gout in adults who have failed or cannot tolerate conventional therapy. The 2022 label permits co-administration with methotrexate in appropriate patients. [1,2]
Key regulatory considerations include:
- Screening for G6PD deficiency before treatment
- Monitoring serum uric acid before each infusion
- Discontinuing treatment when uric acid rises above the labeled threshold
- Managing infusion reactions
- Assessing immunogenicity and loss of response
- Evaluating methotrexate suitability before co-therapy
These requirements support the use of specialty clinics and limit rapid conversion to nonspecialist prescribing.
What generic launch scenarios exist for Krystexxa?
Three launch scenarios are commercially plausible.
Scenario 1: No biosimilar before the late 2020s
This scenario would preserve Amgen’s pricing power. Manufacturing complexity, limited patient volume, and the need for specialized clinical trials could discourage early entry.
Scenario 2: One biosimilar entrant
A single entrant could obtain meaningful payer leverage while preserving a premium for the reference product. Amgen could defend share through contracting, patient-support programs, physician familiarity, and data on methotrexate co-therapy.
Scenario 3: Multiple biosimilars
Multiple entrants would increase discounting and could move treatment toward preferred formulary status. The impact would depend on whether products are interchangeable and whether payers treat infusion-center economics as a reason to favor one product.
A traditional low-cost generic launch is unlikely because pegloticase is a biologic and does not use the ANDA pathway.
What is the geographic coverage and international opportunity?
The United States is the principal commercial market. International expansion is constrained by:
- Country-specific biologic approval requirements
- Reimbursement limits
- Infusion infrastructure
- Lower prevalence of diagnosed refractory gout
- Pricing controls
- Local biosimilar policies
Amgen’s international infrastructure may improve regulatory and commercial coverage outside the United States. The greatest near-term value remains U.S. penetration because the product’s established reimbursement and specialist network are strongest there.
What is the revenue exposure for Amgen?
Krystexxa is strategically important but not financially material to Amgen at the scale of its largest products. Its value lies in durable specialty revenue, growth potential from methotrexate co-therapy, and a differentiated position in refractory gout.
For Horizon, Krystexxa represented a major revenue asset and an important part of the company’s growth narrative. For Amgen, the product is one component of a diversified portfolio. This reduces corporate dependence on Krystexxa but may also reduce the urgency to maximize every incremental patient compared with Horizon’s more concentrated model.
The key financial variables are:
- New patient starts.
- Persistence after the first six months.
- Response rates with methotrexate.
- Gross-to-net discounts.
- Infusion-center economics.
- Biosimilar timing.
- International reimbursement.
- Patent or regulatory barriers affecting competitor entry.
Key Takeaways
- Pegloticase is a high-value biologic for chronic refractory gout, not a first-line gout treatment.
- Krystexxa received FDA approval in 2010 and methotrexate co-therapy approval in 2022.
- Horizon reported approximately $738 million in Krystexxa sales in 2022.
- Amgen completed its acquisition of Horizon in October 2023 and now owns Krystexxa.
- The product’s 12-year U.S. biologic exclusivity period expired in or around 2022.
- Paragraph IV litigation is not the principal entry risk because pegloticase is regulated as a biologic rather than an ANDA drug.
- No approved pegloticase biosimilar was identified in the FDA Purple Book through the latest reviewed records.
- Manufacturing complexity, immunogenicity, infusion requirements, and a specialized patient population may delay biosimilar competition.
- The 2022 methotrexate label expansion improves the product’s response and persistence profile.
- The largest long-term threats are biosimilar entry, better-tolerated uricases, and less burdensome delivery technologies.
FAQs about pegloticase market and patent risk
Is Krystexxa a specialty drug?
Yes. Krystexxa is an infused specialty biologic administered in a controlled clinical setting, with laboratory monitoring and management of infusion reactions.
Can a generic version of pegloticase be approved?
A conventional generic cannot use the standard ANDA pathway. A competing product would generally need to proceed through the FDA biosimilar pathway.
Does methotrexate make pegloticase more commercially competitive?
Yes. Methotrexate can improve sustained response and reduce immunogenicity-related discontinuation, which may increase treatment persistence and revenue per patient.
What is the largest clinical weakness of pegloticase?
Its main weaknesses are infusion burden, immunogenicity, treatment monitoring, and the need to reserve therapy for patients with severe refractory disease.
Will Amgen disclose Krystexxa revenue separately?
Amgen may provide product-level information, but its disclosures are less concentrated than Horizon’s historical reporting. Krystexxa may not receive the same standalone financial detail in every reporting period.
References
-
U.S. Food and Drug Administration. (2024). Krystexxa (pegloticase) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2022). FDA approves methotrexate combination with Krystexxa for chronic refractory gout. FDA.
-
Horizon Therapeutics plc. (2023). Annual report for the year ended December 31, 2022. Horizon Therapeutics.
-
Amgen Inc. (2024). Annual report for the year ended December 31, 2023. Amgen.
-
U.S. Food and Drug Administration. (2024). Reference product exclusivity and biosimilar biological products. FDA.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
-
Horizon Pharma plc. (2015). Horizon Pharma completes acquisition of Krystexxa from Savient Pharmaceuticals. Horizon Pharma.
